Follow Danaher to never miss an important update.
Julie Sawyer Montgomery officially became the company's president and chief executive today, following through on a succession plan first shared in August. She has been with the company since 2017 and most recently led the diagnostics and life sciences segments, which are the core of the business.
Because this was an orderly handover announced months ago, it does not change the outlook for the company. Having a leader who rose through the ranks of its most important divisions suggests the company will stick to its current strategy of selling the specialized tools and supplies used to develop drugs and run medical tests.
Source: PRNewsWire
Danaher's board approved its regular quarterly payout of $0.40 per share. This is a routine move for the company, which uses these steady payments to return a portion of its profits to people who own the stock. To receive this payment, you must be a shareholder of record by September 30.
Source: PRNewsWire
UBS set its price target for the life sciences firm at $250. This is higher than the average analyst target of $224 and well above the current price of about $201. While a price target is just one firm's estimate of what the stock is worth, it reflects a view that the company's core business of selling lab tools and diagnostic tests is undervalued. The stock has struggled this year, but the higher target suggests confidence that growth will return as drug developers ramp up their spending again.
Source: UBS
Danaher reported a change to its executive or director lineup in a recent filing with the SEC, a government agency that tracks company disclosures. These filings are required when a company makes a decision that could be important to its owners, such as a shift in the team responsible for its long-term strategy.
While the filing confirms a change is happening, the company has not yet detailed how this might affect its day-to-day operations. For a business like Danaher, which relies on a specific management philosophy called the Danaher Business System to improve the companies it buys, the stability and quality of its leadership team is a key part of why the business remains efficient.
Source: 8-K filing
The board has chosen Julie Sawyer Montgomery to become the next president and chief executive starting October 1, 2026. She will replace Rainer Blair, who is retiring after leading the company through its recent transformation into a pure-play life sciences and diagnostics business. Blair will stay on as an advisor through March 2027 to help with the handoff.
Montgomery is an internal pick, which suggests the company plans to stick with its current strategy and the Danaher Business System. This system is the company's set of management tools used to constantly improve efficiency and profit. A smooth transition is important right now as the company works to pull out of a post-pandemic slump in its biotechnology equipment sales.
Source: PRNewsWire
Management has a perfect record of clearing their own targets for two years straight. They consistently set a bar they can beat by a comfortable margin, making their forecasts highly reliable.
| Expectation | |
|---|---|
| EPS | $1.91 |
| Revenue | $6.55B |